We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Bacterial Toxin Targets Discovered
News

Bacterial Toxin Targets Discovered

Bacterial Toxin Targets Discovered
News

Bacterial Toxin Targets Discovered

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Bacterial Toxin Targets Discovered"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Research that provides a new understanding of how bacterial toxins target human cells is set to have major implications for the development of novel drugs and treatment strategies.

Cholesterol-dependent cytolysins (CDCs) are toxins produced by major bacterial pathogens, most notably Streptococcus pneumoniae and group A streptococci, which collectively kill millions of people each year.

The toxins were thought to work by interacting with cholesterol in target cell membranes, forming pores that bring about cell death.

Published today in the prestigious journal Proceedings of the National Academy of Sciences, the research is an international collaboration between the University of Adelaide's Professor James Paton and Professor Michael Jennings from Griffith University, and collaborators at the University of Queensland and Department of Microbiology, New York University School of Medicine.

The team has, for the first time, shown that these toxins require binding to specific glycans (sugar structures) on the cell surface for efficient targeting of the host.

This explains why some cell types are more susceptible to the toxins than others, and also provides opportunities to develop novel drugs capable of blocking toxin-glycan interactions, thereby protecting host cells from toxin-mediated damage.

Professor Jennings, Deputy Director of the Institute for Glycomics at Griffith University, says these findings open up a completely novel approach to developing drugs which may block toxin action.

"Understanding how toxins target particular cells in the human body is the first step in understanding their mechanism of action and how to block them from causing cell death."

Professor Paton, Director of the University of Adelaide's Research Centre for Infectious Diseases, says: "Interactions between CDCs and glycan receptors on immune cells also explains why these toxins have additional effects on host responses to infection, which enable the pathogenic bacteria to 'fly under the radar' of host immune defences."

Advertisement